MedX Health Strengthens Its Senior Management Team
MedX Announces Tarek El Hoss as Sr. Vice President, Market Development and Sales
MISSISSAUGA, Ontario, August 02, 2022--(BUSINESS WIRE)--MedX Health Corp. ("MedX" or the "Company") (TSXV: MDX), a global leader in teledermatology, is pleased to announce that Tarek El Hoss has been appointed as the Company’s Vice President, Market Development and Sales. Mr. El Hoss will oversee strategic global growth initiatives and will be responsible for the deployment of market development strategies to impact immediate revenue generation and growth.
Mr. El Hoss has over 20 years of demonstrated success in the medical technology industry, including a lengthy tenure as Business Director, Middle East, Africa, Central Asia and Turkey for Medtronic where he was responsible for implementing and driving sales strategies while establishing distribution channels and launching new products throughout his geography of responsibility.
"Over the past year, we’ve announced commercial partnerships to make our DermSecure skin screening technology available to serve patients throughout Europe, the Middle East and Canada," said MedX President and CEO Naman Demaghlatrous. "Tarek’s extensive knowledge of the global medical technology marketplace and proven expertise in establishing country specific go-to-market strategies will be crucial to the next phase of our company’s growth and we’re delighted to have him join our team."
"I am excited to join a dynamic team that is driven by a global mindset," stated Mr. El Hoss. "Leveraging and strengthening our existing partnerships while seeking out and building others will improve access to our best-in-class, innovative teledermatology platform for patients around the world. I am looking forward to expanding MedX’s international footprint and offering a solution to improving patient outcomes at the same time."
MedX’s leading telemedicine platform allows health-care practitioners to quickly and accurately assess suspicious moles, lesions and other skin conditions via its image-capture technology, SIAscopy®, and its secure, cloud-based patient management system, DermSecure®, which transmits and stores patient data throughout the assessment process. MedX’s SIAscopy® is the only technology that captures five images, including four spectrophotometric images 2mm below the skin’s surface. Teledermatology is a subspecialty of dermatology that offers safe and effective virtual patient assessment and diagnosis at a distance, eliminating the need for in-person appointments.
About MedX Health Corp.
MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view suspicious moles and lesions up to 2mm beneath in a pain-free, non-invasive manner. Its patented software then creates real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union, Brazil and Turkey. Visit www.medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220802006122/en/
Bill Mitoulas, Investor Relations
MedX Health Corp.